Su He Xiang (Liquidambar orientalis / Storax) Pharmacology

— Styracin, cinnamyl cinnamate, free cinnamic acid and the Anatolian sweetgum balsam behind Su He Xiang Wan and the aromatic-resuscitation liniment tradition.

Open the Tai Ping Hui Min He Ji Ju Fang (太平惠民和劑局方, Song dynasty) at the prescription Su He Xiang Wan (蘇合香丸) — for centuries the canonical emergency formula for “sudden collapse from cold-pathogen, lockjaw, qi-stagnation chest pain” — and the eponymous ingredient is an imported aromatic resin called Su He Xiang (蘇合香). It is not a Chinese plant. The original material entered China along the Silk Road from Anatolia and Persia, where it was tapped from the wounded trunk of Liquidambar orientalis Mill., a small Hamamelidaceae tree endemic to the southwestern coast of Turkey.

That geographic origin matters more than any other identity feature you will read in this article. Roughly 95% of the resin sold in Asian markets under the label “Su He Xiang” is not Turkish L. orientalis. It is most often Liquidambar formosana resin (枫香脂, Feng Xiang Zhi — the source of the gallnut-like Lu Lu Tong fruit, a separate Pharmacopoeia article), American sweetgum balsam from L. styraciflua, or a blend of cinnamic-acid-rich resins re-extracted and re-coloured. The constituents overlap heavily, but they are not identical, and the regulatory and pharmacological standing of the four resins is not the same.

This article does three things. First, it locks down the identity of the four “storax” articles you will encounter, so you know what is actually in the bottle when a formulary calls for 蘇合香. Second, it walks through the cinnamic-acid-ester chemistry and the modern pharmacology — anti-thrombotic, anti-inflammatory, NF-κB-suppressing, PPARα-activating. Third, it puts the resin back into its real role in topical medicated-oil formulation: a fixative aromatic, used sparingly, and almost always in combination with the closely related (but distinct) An Xi Xiang (benzoin).

1. Identity: four resins, one trade name

1.1 Su He Xiang proper — Liquidambar orientalis Mill.

Botany: Liquidambar orientalis Mill., family Hamamelidaceae. Small deciduous tree, native almost exclusively to the wetland forests of southwestern Anatolia (Muğla Province, Turkey) and rarely Rhodes.
Material: balsamic resin obtained by wounding the trunk and stripping the inner-bark layer, then steam-pressing or alcohol-extracting the impregnated bark.
Macroscopic: thick, viscous semi-fluid, greyish-brown to dark brown, sticky, semi-transparent, threads when stirred, aromatic-cinnamon odour with a balsamic finish.
Chinese Pharmacopoeia (2020 ed.) status: the defining article under the name 蘇合香. Standard requires cinnamic acid content ≥ 5.0% by HPLC.
Conservation: L. orientalis is IUCN-listed as Vulnerable. Wild stands have collapsed under tannery demand, fire and habitat conversion. Authentic supply is therefore tight and expensive.

1.2 Feng Xiang Zhi — Liquidambar formosana Hance

Botany: Liquidambar formosana Hance, the Chinese / Taiwanese sweetgum, distributed across central and southern China, Taiwan, Korea, Vietnam.
Material: resin tapped from the trunk; the dried fruit infructescence is the separate article Lu Lu Tong (路路通), used quite differently as a wind-damp channel-opener.
Pharmacopoeia status: the resin is a separate Pharmacopoeia article called 枫香脂. It is not a legal substitute for 蘇合香, although in practice traders relabel it.
Chemistry: broadly similar cinnamic-acid-ester profile, but with a higher fraction of triterpene acids (oleanolic, betulinic) and a substantially lower content of free cinnamic acid.

1.3 American storax — Liquidambar styraciflua L.

North American sweetgum. The commercial “Honduras storax” or “American storax” of the 19th- and 20th-century pharmacopoeias is in fact obtained from this species, often in Central American plantations.
Has been traded into East Asian markets as “Su He Xiang” since at least the late Qing. Chemistry is close enough that early Western pharmacopoeias accepted it as interchangeable, but the resin is not legal under the modern Chinese Pharmacopoeia.

1.4 An Xi Xiang — Styrax benzoin Dryand. and S. tonkinensis

The single most common confusion. An Xi Xiang (安息香, benzoin) is a balsamic resin from Styrax species, family Styracaceae — a botanically unrelated family. It is dominated by benzoic acid and benzyl benzoate rather than cinnamic acid esters, and has its own monograph and its own clinical role (see the separate article on An Xi Xiang pharmacology). The two are repeatedly conflated in English-language literature because of the synonymous use of “storax” and “styrax” in Linnaean nomenclature, but they are chemically and clinically distinct.

Sourcing rule for the formulator: if your formula calls for 蘇合香 (Su He Xiang), the latin binomial on the certificate of analysis must be Liquidambar orientalis and the HPLC trace must show cinnamic acid as the dominant acid peak. Anything labelled “L. formosana”, “L. styraciflua” or “Styrax benzoin” is a different ingredient with a different monograph.

2. Phytochemistry: a cinnamic-acid-ester resin

Authentic L. orientalis balsam is roughly two-thirds resinous matter and one-third volatile and semi-volatile esters. The constituent classes are:

2.1 The cinnamic-acid-ester core

Compound	Approximate share	Note
α- and β-storesin and their cinnamic esters	33–50%	Polymeric triterpene alcohols esterified to cinnamic acid; the “balsam body”
Styracin (cinnamyl cinnamate)	5–10%	The lead crystalline ester; gives the resin its sweet-balsamic top note
Ethyl cinnamate	up to ~10%	Together with phenylpropyl cinnamate; lighter, more volatile
Phenylpropyl cinnamate	within the ester fraction	Mid-volatility, contributes to long fixative action
Benzyl cinnamate	minor
Free cinnamic acid	5–15%	The Pharmacopoeia marker compound; minimum 5.0% by HPLC

2.2 Minor volatile constituents

A levorotatory essential oil (≈ 0.4%) containing styrene, vanillin and small amounts of monoterpenes.
Trace vanillin — responsible for the characteristic sweet undertone of authentic Turkish storax that adulterants generally lack.
Small fractions of cinnamaldehyde and styrol.

2.3 What is not in authentic Su He Xiang

Benzoic acid as a dominant peak (that signals An Xi Xiang, Styrax benzoin).
Aristolochic acids (no botanical reason for them to be present; their detection in a “Su He Xiang” sample indicates contamination or substitution).
Large eugenol or methyl eugenol peaks (would indicate adulteration with clove- or cinnamon-leaf-derived material).

3. Pharmacology: NF-κB, PPARα and the cinnamic-acid axis

3.1 Anti-inflammatory and neuroprotective: NF-κB suppression

The most thoroughly studied modern pharmacology of Su He Xiang is its neuroprotective action in cerebral ischaemia models, mirroring the classical use of Su He Xiang Wan for “sudden collapse” (中風閉證). In an oxygen-glucose deprivation / re-oxygenation (OGD/R) primary astrocyte model, storax extract dose-dependently:

reduced LDH release and improved cell viability,
suppressed phosphorylation and nuclear translocation of NF-κB p65,
downregulated downstream iNOS, COX-2 and TNF-α.

Cinnamic acid and its esters are the proximate actors — they cross the cell membrane easily, deacetylate to free cinnamic acid intracellularly, and interrupt the IKK-β / NF-κB cascade upstream of cytokine transcription. The functional consequence is reduced inflammatory amplification in the penumbra around an infarct, which fits the classical “open the orifices, dispel cold-turbid blockage” indication of the parent formula.

3.2 Antithrombotic and cardioprotective

Grafted-trunk L. orientalis studies have shown that storax extract:

prolongs activated partial thromboplastin time (APTT) and thrombin time (TT) in rat plasma,
inhibits ADP- and arachidonic-acid-induced platelet aggregation,
reduces infarct size in isoproterenol-induced myocardial-infarction rat models, with parallel reductions in serum CK-MB, LDH and cardiac troponin I.

This pharmacology underpins the modern repurposing of Su He Xiang Wan as an emergency formula for early-stage acute coronary syndrome in some Chinese hospitals, though the evidence base is still pre-clinical and small-trial.

3.3 PPARα activation and amyloid clearance

Free cinnamic acid is a PPARα agonist. In transgenic mouse models of Alzheimer’s disease, cinnamic acid administration upregulated PPARα-dependent lysosomal biogenesis (TFEB activation, increased CTSD and LAMP1 expression) and reduced cortical Aβ plaque load. This is mechanistically interesting because it offers a non-classical channel by which an aromatic resin used externally for “wakening the spirit” might converge with neurodegenerative pharmacology — though clinical translation is still distant.

3.4 Antibacterial and topical anti-inflammatory

In broth-dilution and disc-diffusion screens, storax ethanolic extract has shown:

MIC values of 1–4 mg/mL against Staphylococcus aureus (including some MRSA strains) and Streptococcus pyogenes,
mild activity against Candida albicans,
topical anti-inflammatory effect in croton-oil-induced mouse ear oedema (≥ 40% inhibition at 10% w/w).

These activities are unsurprising — they are the activities of any cinnamic-acid-rich balsamic resin (compare Peru balsam, Tolu balsam, benzoin) — and they explain the long-standing topical use of crude storax in Anatolian folk medicine for slow-healing wounds and chronic dermatitis.

3.5 Toxicology

Acute oral LD50 in rodents for storax extract is in the multi-gram-per-kilogram range (low acute toxicity). Topical sensitisation rates in patch-test surveys of cosmetic-grade “Peru balsam / storax / styrax” mixtures are non-trivial (around 1–4% in dermatology referral populations) — this is a classic balsam-of-Peru-type contact allergy and is the main practical safety concern for topical formulators.

4. Role in topical medicated-oil formulations

In Chinese topical practice, Su He Xiang is not a workhorse anti-inflammatory like menthol, camphor or methyl salicylate. It is an aromatic fixative and “orifice-opener” used at very low percentages, typically 0.1–0.5% w/w in a finished medicated oil or balm. Three reasons:

Cost and scarcity. Authentic Turkish L. orientalis balsam runs to several hundred US dollars per kilogram at wholesale, often more.
Olfactory weight. At 1% and above the cinnamic-cinnamon-balsamic note dominates the entire base and crowds out menthol and camphor freshness.
Sensitisation risk. Pushed above 1% in a leave-on product, the balsam-of-Peru-type cross-reactivity becomes a measurable allergen burden.

Its actual functions in a finished medicated oil:

Aromatic anchor. Pinned at 0.1–0.3% it slows the evaporation of menthol, camphor and eucalyptus, giving the rub a longer-perceived “warmth” on skin.
Symbolic completion of the “opening the orifices” function in a formula that already contains borneol (冰片), musk-substitute (合成麝香) or styrax-benzoin (安息香) — particularly in modernised versions of the Su He Xiang Wan tradition reformulated as topical chest balms for angina-like complaints.
Counterirritant trace component in some Tibetan-style musculoskeletal oils, where it sits beside frankincense, myrrh and benzoin.

You will rarely encounter it as a single named ingredient on a Western pharmacy shelf; you will encounter it inside compound TCM topical balms, where it usually appears low on the ingredient list immediately after the borneol/camphor pair.

5. Practical sourcing and dose guidance

Source material spec: Liquidambar orientalis Mill. balsam, Pharmacopoeia-grade, HPLC certificate showing cinnamic acid ≥ 5.0%, free of L. styraciflua / L. formosana / Styrax benzoin substitution.
Storage: airtight glass, 15–25 °C, away from direct light. The resin oxidises slowly; rancid or sour odour indicates degradation and the material should be discarded.
Topical dose: 0.1–0.5% in finished leave-on oils and balms. Above 1% expect olfactory dominance and rising sensitisation risk.
Pregnancy: the parent formula Su He Xiang Wan is contraindicated in pregnancy on classical grounds (it contains warming aromatic orifice-openers and qi-mobilising agents). The isolated resin at topical 0.1–0.3% in a non-abdominal application is unlikely to pose direct foetal risk, but in the absence of dedicated reproductive toxicology data the conservative recommendation is to avoid abdominal or low-back application during pregnancy and to skip it entirely in the first trimester.
Patient warning: disclose to patients with known balsam-of-Peru, benzoin, Peru-balsam or fragrance-mix contact dermatitis.

6. Bottom line

Su He Xiang is the cinnamic-acid-ester balsam from Liquidambar orientalis, an Anatolian Hamamelidaceae tree whose vulnerable wild populations have made authentic supply scarce and expensive. Its pharmacology — NF-κB-suppressing neuroprotection, antithrombotic platelet inhibition, PPARα-mediated metabolic and neurodegenerative effects, mild antibacterial and topical anti-inflammatory action — is the pharmacology of free cinnamic acid and its high-molecular-weight esters, and is broadly shared with the related but legally distinct L. formosana, L. styraciflua and the unrelated Styrax benzoin.

In topical medicated-oil work it earns its place as a low-percentage aromatic fixative and “orifice-opener”, typically at 0.1–0.5% inside a compound balm or chest oil — not as a primary analgesic. The discipline that separates a good formulation from a poor one is identity: confirm the Latin binomial, demand the HPLC trace, distinguish it clearly from benzoin (An Xi Xiang) and Feng Xiang Zhi (the Chinese sweetgum resin), and document the substitution if you cannot source the Turkish article.

Sources: